Replies to post #69994 on Biotech Values

[DewDiligence]

>…looking at the efficacy & safety profiles of the two doses, perhaps NVS should test a lower than 0.5mg dose.<

Too late for that now—the lowest dose in the FREEDOMS and FREEDOMS-2 trials—as well as their open-label extension studies—is 0.5mg.

The 1.25mg dose is probably dead from a commercialization standpoint.

[DewDiligence]

FTY720 slides from yesterday’s NVS CC:

http://www.novartis.com/downloads/investors/presentations-events/other-events/2008/2008-12-11-FTY720-transforms-initial-results.pdf